Literature DB >> 19437096

Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer.

Amir H Khandani1, William K Funkhouser, Richard Feins, Mark A Socinski.   

Abstract

A 78-year-old man with a history of prostate cancer and a rise in PSA presented with a new left lung mass, detected on computed tomography (CT). Positron emission tomography (PET)-CT (PET-CT) scan with 18-F fluorodeoxyglucose glucose revealed intense uptake in the lung mass without any other areas of abnormal uptake. Surgical resection of the mass and mediastinal lymph node dissection revealed metastatic adenocarcinoma from prostate cancer in the left lung mass (tumor size 5 cm) as well as in a subcarinal lymph node (tumor size 1.9 cm), which were identical on hematoxylin and eosin stains with a Gleason score of 8. The size of the subcarinal lymph node metastasis could not explain its non-visualization on PET. Glut1 stains of the lung mass were positive with moderate (2+ out of maximum 3+) reactivity in 95% of the carcinoma cells, whereas Glut1 stains of the subcarinal lymph node were negative with faint (1+ out of maximum 3+) reactivity in ca. 30% of the carcinoma cells. The low Glut1 expression in the subcarinal lymph node is the most likely explanation for its non-visualization on PET.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437096     DOI: 10.1007/s12149-009-0264-2

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  6 in total

1.  The role of resection of pulmonary metastases from prostate cancer: a case report and literature review.

Authors:  Christopher J D Wallis; John C English; S Larry Goldenberg
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

Review 2.  [Resection of metastases from prostate cancer].

Authors:  C-H Ohlmann; S Siemer; M Stöckle
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

3.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 4.  Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.

Authors:  Amir H Khandani; W Kimryn Rathmell
Journal:  Semin Nucl Med       Date:  2012-07       Impact factor: 4.802

Review 5.  Solitary pulmonary metastasis from prostate cancer with neuroendocrine differentiation: a case report and review of relevant cases from the literature.

Authors:  Toshiya Maebayashi; Katsumi Abe; Takuya Aizawa; Masakuni Sakaguchi; Naoya Ishibash; Shoko Fukushima; Taku Honma; Yoshiaki Kusumi; Tsuyoshi Matsui; Nozomu Kawata
Journal:  World J Surg Oncol       Date:  2015-05-07       Impact factor: 2.754

6.  Glucose transporters as markers of diagnosis and prognosis in cancer diseases.

Authors:  Leszek Szablewski
Journal:  Oncol Rev       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.